AI-generated summary
The authors tested a higher dose (125J) of 670nm near-infrared light delivered through an implanted fiber in 15 MPTP-treated monkeys, a model of Parkinson's disease. They report the higher dose did not harm midbrain cells and increased tyrosine hydroxylase-positive nigral cells, but showed little improvement in clinical scores or other measures compared with lower doses. The authors describe this dose as less beneficial than the 25J and 35J doses they studied previously.
- Participants
- 15
- Who or what was studied
- Macaque monkeys in a subacute MPTP model of Parkinson's disease
- Wavelengths
- 670 nm
- Limits stated in the abstract
- The study uses an animal model with a small sample of 15 monkeys, and the abstract reports limited evidence of benefit at the higher dose.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 670nm
- Total energy
- 25J, 35J, 125J
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Near-infrared, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.